Lung Diseases Cies Search Engine [selected websites]


May 25, 2010

Galapagos and Roche : COPD alliance

Galapagos NV11 May 2010 – Galapagos NV (Euronext: GLPG) announced that it has expanded its global multi-year strategic alliance with Roche (SIX: RO, ROG; OTCQX:RHHBY) to develop potential new therapies in COPD (chronic obstructive pulmonary disease). The partners have increased the number of antibody targets in the alliance. In addition, these targets can now also be used as starting points for molecules consisting of nucleic acids and/or amino acids. As such, the scope of molecules subject to this alliance could potentially include also peptides, siRNA and other nucleic acids.

Galapagos and Roche started their strategic alliance in COPD in January 2010. Galapagos is applying its target discovery platform to discover novel COPD targets and is responsible for the discovery and development of new small molecule candidate drugs against these targets. Roche has an exclusive option to license each small molecule program after either clinical candidate selection or completion of Phase I clinical trials. In addition, Roche has an exclusive option to license the COPD targets for the discovery and development of antibodies against these targets. Upon exercise of each option, Roche will be responsible for the further (pre)clinical development and commercialization. Galapagos received a research access payment of €6 million from Roche upon signature of the alliance. The alliance expansion announced today has the potential to increase the total value of milestone payments Galapagos receives under this agreement by €150 million... Galapagos' Press Release -